Physician profile
Danielle Vilsaint
NPI 1255695276
$2,807.95
in general payments reported to CMS, 2019-2025
17 companies · $635 in 2025
The $635 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $598 · 2022: $409 · 2023: $107 · 2024: $1,058 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $958.19 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $401.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.91 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $234.48 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $164.27 | 2021-2024 | |
| Amarin Pharma, INC. | $162.91 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.74 | 2022-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $79.92 | 2021 | |
| Exact Sciences Corporation | $67.70 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $62.39 | 2023-2024 | Otezla, Repatha |
| Eisai INC. | $53.15 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.98 | 2022 | |
| Viiv Healthcare Company | $26.00 | 2025 | Apretude |
| Global Blood Therapeutics, INC. | $24.12 | 2021 | |
| Genentech USA, INC. | $23.01 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.61 | 2021 | |
| Glaxosmithkline, LLC. | $16.13 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Vilsaint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.